Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPFT vs Surgery for Pleural Infection
NCT03873766Phase 4Completed
- Sponsor
- Swedish Health Services
- Start
- Apr 2019
- Primary completion
- Mar 2022
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tissue-plasminogen activator and dornase alfa in pleural infection, empyema and parapneumonic effusion (2 arms), sponsored by Swedish Health Services. Primary endpoints: Feasibility of the proposed study algorithm at 1 year and Subject identification and accrual at 1 year. Started Apr 2019; status: completed.
02
Drugs
tissue-plasminogen activatordornase alfa
03
Conditions
pleural infectionempyemaparapneumonic effusion
Beyond the preview
Go deeper on NCT03873766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873766.